stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) EV/FCF
As of 5 November 2026, Veracyte, Inc. (VCYT) trades at a EV/FCF of 9.0×. Over the past ten years it has ranged from −1,794× (February 2023) to 248× (June 2023); the current reading is higher than 70% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 22.9× | (46.74%) |
| FY2024 | 43.0× | (17.13%) |
| FY2023 | 51.8× | — |
| FY2022 | −1,424× | — |
| FY2021 | −70.9× | — |
| FY2020 | −180× | — |
| FY2019 | −190× | — |
| FY2018 | −26.8× | — |
| FY2017 | −8.7× | — |
| FY2016 | −6.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 19.9× | (21.60%) |
| Jun 2026 | 25.4× | 85.57% |
| Mar 2026 | 13.7× | (40.22%) |
| Dec 2025 | 22.9× | (3.89%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| NEO NeoGenomics, Inc. compare | −96.9× |
| WGS GeneDx Holdings Corp. compare | −25.0× |
| GRAL GRAIL, Inc. compare | −15.9× |
| VCYT Veracyte, Inc. | 9.0× |
| SHC Sotera Health Company compare | 47.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| BLLN BillionToOne, Inc. compare | 142× |
| RDNT RadNet, Inc. compare | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement